COVID-19 Infection
Conditions
Keywords
COVID-19, coronavirus infection, respiration, artificial, extracorporeal membrane oxygenation, randomized controlled trial, respiratory distress syndrome, adult
Brief summary
The purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance). We are proposing to try this drug to treat coronavirus disease 2019 (COVID-19) infection. Patients with COVID-19 infection have been shown to have increases in certain inflammatory processes. Clazakizumab is an antibody (immune system protein) that blocks certain inflammatory processes. The treatment plan is to attempt to inhibit or block these inflammatory processes in order to try to limit the damage COVID-19 causes to the lungs.
Detailed description
The purpose of this randomized, double-blind, placebo-controlled trial is to evaluate the safety and efficacy of clazakizumab vs placebo for the prevention of acute respiratory distress syndrome (ARDS) in patients with COVID-19 and pulmonary manifestations. The study will compare clazakizumab to placebo in a randomized, double-blind fashion followed by an open-label dose of clazakizumab if there is no improvement or a worsening of condition occurs after 24-hours or anytime during the first 14 days after the first dose of clazakizumab or placebo. We hypothesize that clazakizumab will be safely tolerated and will reduce the risk of progression of COVID-19 to acute respiratory distress syndrome. Primary Objective: • To evaluate the safety and tolerability of clazakizumab vs placebo for the treatment of patients with COVID-19 disease and signs of pulmonary involvement Sixty adult patients with COVID-19 and signs of pulmonary involvement at Houston Methodist who are not in need of ventilator support at the time of enrollment.
Interventions
DRUGClazakizumab
Infusion
DRUGPlacebo
Infusion
Sponsors
The Methodist Hospital Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Blinded to all except investigational pharmacy. Only the optional second infusion, if determined necessary to administer, will be open-label. The patient and study team will remain blinded until data lock at the end of the study.
Intervention model description
This single-site, phase 2 randomized, double-blind, placebo-controlled trial is designed to administer a single dose of clazakizumab or placebo on day 0. If, after 24 hours or up to 14 days from the first infusion, the participant's condition worsens or does not improve, the investigator may elect to provide a single, open-label dose of clazakizumab regardless of the initial group assignment. All except the investigational pharmacist will remain blinded as to the initial group assignment until data lock.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>18 at the time of screening. 2. Participant or legally authorized representative (LAR) must be able to understand and provide informed consent. 3. Hospitalized with coronavirus disease (COVID-19) confirmed by polymerase chain reaction (PCR) assay from any specimen (eg, respiratory, blood, urine, stool, other bodily fluid) within the prior 72 hours. 4. C-reactive protein (CRP) \> 3.5 mg/dL 5. Evidence of pulmonary involvement with at least 2 of the following: 1. oxygen saturation at rest in ambient air with peripheral capillary oxygen saturation (SpO2) ≤ 94% 2. tachypnea with resting respiration rate \> 25 breaths/minute 3. Partial pressure of oxygen (PaO2)/initial fraction of inspired oxygen (FiO2) ≤ 300 mmHg 4. Chest imaging (radiograph, CT, or ultrasound) with abnormalities consistent COVID-19 pneumonia
Exclusion criteria
1. Previous hypersensitivity or allergic reactions to clazakizumab 2. Lactating or pregnant females 3. Patients with latent tuberculosis (TB) and who are not receiving treatment 4. Patients with active TB 5. Patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation 6. Requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 7. A significantly abnormal general serum screening lab result defined as a white blood cell (WBC) count \< 3.0 X 10\^3/mL, a hemoglobin (Hgb) \< 8.0 g/dL, a platelet count \< 50 X 10\^3/mL, an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 5 times upper limit normal 8. Participation in another clinical trial investigating COVID-19-aimed agents 9. Presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Endpoint | 24 hours | Proportion of participants who experience treatment-related adverse events (TEAE) ≥ Grade 3 (CTCAE v5.0) during the first 24 hours after infusion of clazakizumab or placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Infusion-related reactions during 24 hours from the time of infusion | 24 hours | Proportion of participants who experience infusion-related reactions during the first 24 hours after infusion of clazakizumab or placebo |
| Patient survival at 28 days | 28 days | Proportion of participants alive at day 28 after the first dose of clazakizumab or placebo |
| Patient survival at 60 days | 60 days | Proportion of participants alive at day 60 after the first dose of clazakizumab or placebo |
| Requirement for open-label clazakizumab | 14 days | Proportion of participants who require an open-label dose of clazakizumab |
| Time in the intensive care unit (ICU) | 60 days | Number of days in the ICU following the first dose of clazakizumab or placebo |
| Requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) | 14 days | Proportion of participants who need mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) after the first dose of clazakizumab or placebo |
| Time to mechanical ventilation | 60 days | Number of days from first dose of clazakizumab or placebo to requiring mechanical ventilation |
| Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14 | 14 days | Difference in WHO Clinical Progression Scale between clazakizumab and placebo |
| Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28 | 28 days | Difference in WHO Clinical Progression Scale between clazakizumab and placebo |
| Change in Radiologic Assessment of Lung Edema (RALE) at day 14 | 14 days | Difference in mean or median change in radiologic assessment of lung edema (RALE) score at day 14 from baseline between clazakizumab or placebo |
| Change in Radiologic Assessment of Lung Edema (RALE) at day 28 | 28 days | Difference in mean or median change in radiologic assessment of lung edema (RALE) score at day 28 from baseline between clazakizumab or placebo |
| Time in the hospital | 60 days | Number of days in the hospital following the first dose of clazakizumab or placebo |
Countries
United States
Contacts
Primary ContactIsioma Agboli, MD
Backup ContactDarrel Cleere, BSN
Outcome results
None listed